By
Kyle Brasseur2023-09-28T20:59:00
Out-of-home advertising company Clear Channel Outdoor Holdings agreed to pay more than $26 million as part of a settlement with the Securities and Exchange Commission (SEC) alleging its former China-based subsidiary bribed government officials to obtain outdoor advertising contracts.
Clear Channel was fined $6 million, in addition to agreeing to disgorge approximately $16.4 million and pay prejudgment interest of approximately $3.8 million, for violating the Foreign Corrupt Practices Act, the SEC announced in a press release Thursday.
The agency cited the company for anti-bribery, recordkeeping, and internal accounting control violations.
2024-01-25T18:01:00Z By Aaron Nicodemus
Enforcement actions regarding alleged violations of the Foreign Corrupt Practices Act at 3M, Albemarle, Clear Channel Outdoor, and Royal Philips each had China touchpoints. Experts assess third-party risk management lessons learned from each case.
2023-11-08T14:45:00Z By Jaclyn Jaeger
Lack of transparency around how to remain within the legal bounds of China’s national security laws has heightened companies’ concerns regarding performing on-site due diligence in the country.
2023-11-01T16:06:00Z By Kyle Brasseur
GE HealthCare said it is cooperating with reviews by the Department of Justice and Securities and Exchange Commission into potential violations of the Foreign Corrupt Practices Act in China.
2025-11-05T18:35:00Z By Oscar Gonzalez
Approximately $9 billion of potential shadow-banking flows tied to Iranian networks in 2024, according to a new analysis from FinCEN. The report highlights how illicit funds are making their way through financial institutions as they meet the requirements of the Bank Secrecy Act (BSA).
2025-10-31T18:52:00Z By Oscar Gonzalez
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
2025-10-30T19:59:00Z By Oscar Gonzalez
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.
Site powered by Webvision Cloud